

28AB-ISMS19 **Module Technology for Oncology Drug Discovery**

○Masakazu FUKUSHIMA¹, Kenzo IIZUKA¹, Chung ZHANG¹, Cheng JIN¹, Kiyoshi ESHIMA¹

¹Delta-Fly Pharma, Inc.

Module technology has been applied for innovative invention of motor cars and telephones. Nowadays, people are enjoying their driving of hybrid cars, electric cars and hydrogen fuel driven cars without any concern about any drain on resources and destruction of the environment. People are enjoying their pleasant communication by using of iPhone. These kind of module technology based industrial revolution guided wonderful quality of line for human.

On the other hand, it's highly regrettable, but almost of cancer patients are not always satisfactory with current cancer chemotherapy. For the cancer patients, it should be improved existing anti-cancer drugs from the view point of efficacy/side effect balance and cost of anti-cancer drugs, especially, molecular targeting antibody.

Our objective is to apply our own module technology for oncology drug discovery for terminal stage cancer patients without any serious side effect. Our major oncology pipeline as follows;

- DFP-10917 (P-II, AML): Cell cycle regulator (G2/M arrest).
- DFP-11207 (P-I): Oral 5-FU derivative without any diarrhea and thrombocytopenia.
- DFP-13318 (P-I): Polymer derivative of SN-38 without any diarrhea.
- DFP-10825: (Pre-clinical): RNAi/DDS.